Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Mattía Galli(Maria Cecilia Hospital), Sebastiano Sciarretta(Istituto Neurologico Mediterraneo), Roxana Mehran(Icahn School of Medicine at Mount Sinai), Gianmarco Sarto(Sapienza University of Rome), Domenico D’Amario(Università Cattolica del Sacro Cuore), Claudio Laudani(University of Catania), Filippo Crea(Università Cattolica del Sacro Cuore), Massimo Federici(University of Rome Tor Vergata), Erica Rocco(Sapienza University of Rome), Marco Bernardi(Policlinico Umberto I), Ernesto Greco(European University of Rome), Giacomo Frati(Istituto Neurologico Mediterraneo), Stefano Benenati(University of Genoa), Dominick J Angiolillo(University of Florida), Luis Ortega‐Paz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Beatrice Simeone(Sapienza University of Rome), Luigi Spadafora(Policlinico Umberto I)
Cited by 48
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k